Lynda Charters

A large retrospective analysis was carried out to investigate various risk factors for endophthalmitis as well as the effect of using a hydrogel sealant.

Lower dose of bevacizumab is as effective as a higher dose for treating retinopathy of prematurity.

Successful outcomes in rhino-orbital-cerebral mucormycosis depend on awareness of red flag symptoms and signs, prompt diagnosis and early treatment with amphotericin B and surgery as necessary.

Dr Taiichi Hikichi counteracted the potential inflammatory effect of brolucizumab by combining its administration with a sub-Tenon’s capsule injection of triamcinolone acetonide.

Assessing cornea status can aid early recognition of disease-related changes.

Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

The drug is prescribed as adjunctive therapy for those with glaucoma.

Researchers believe that the prolonged effect of bimatoprost may result from up-regulation of matrix metalloproteinases, leading to sustained remodelling of the outflow pathways.

Sub-retinal injection of adeno-associated virus leads to visual acuity gains.

A team of investigators has found that the eye disease is more prevalent than first thought.

Retinal changes seen in suspected transient ischaemic attacks are not helpful for predicting ischaemic events.

According to Dr Claudia Perez-Straziota, persistent epithelial defects do not have to live up to their name—they can be healed.

Utilizing new technology, surgeons can be 20 to 40 times more precise.

Researchers compared two novel lens designs using data obtained from 19 investigational sites in Australia, Canada, Spain and the UK.

Novel treatment reduces treatment burden and improves outcomes.

Intracanicular insert is the first physician-administered, preservative-free method.

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.

KALAHARI study finds THR-149 to be safe, well-tolerated with preliminary efficacy as treatment for DMO patients who respond suboptimally to anti-VEGF.

Faricimab is the first bispecific antibody designed for intraocular use that blocks 2 pathways, the angiopoietin-2 (Ang-2) and the vascular endothelial growth factor (VEGF) A pathways.

Most patients who had received monthly injections, that is, 92%, preferred the PDS after switching, with 88% having a very strong preference.

Previously treated patients showed significantly reduced treatment burden.

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation and Degeneration 2022 Virtual Edition, Dr Glenn J. Jaffe noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.

This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.

A once-daily oral drug targets inflammatory processes and thus far has been found to be well tolerated in a Phase 2 safety trial.

A new home telemedicine system generates valuable data on disease and the dynamics of fluid exudation.

Government, academia and industry team up to streamline gene therapy development.

The improvement became evident during an average time of 6 months.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

Ophthalmologists gather to discuss neovascular and exudative diseases of the eye and the revolutionary therapies on the horizon.